These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
973 related articles for article (PubMed ID: 31282617)
1. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617 [TBL] [Abstract][Full Text] [Related]
2. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357 [TBL] [Abstract][Full Text] [Related]
3. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593 [TBL] [Abstract][Full Text] [Related]
4. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633 [TBL] [Abstract][Full Text] [Related]
5. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549 [TBL] [Abstract][Full Text] [Related]
6. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649 [TBL] [Abstract][Full Text] [Related]
7. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. Monés J; Biarnés M; Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111 [TBL] [Abstract][Full Text] [Related]
12. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. Bro T; Hägg S Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333 [TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561 [TBL] [Abstract][Full Text] [Related]
14. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167 [TBL] [Abstract][Full Text] [Related]
15. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study. Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465 [TBL] [Abstract][Full Text] [Related]
16. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial. Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R; JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration. Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S; Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183 [TBL] [Abstract][Full Text] [Related]
19. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies. Steinle NC; Du W; Gibson A; Saroj N Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314 [TBL] [Abstract][Full Text] [Related]
20. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]